Login to Your Account

Azar: Part D may be a model for Part B drug pricing problem

By Mark McCarty
Regulatory Editor

Wednesday, November 29, 2017

The hearing for Alex Azar as the Secretary of Health and Human Services revolved in large part around the drug pricing controversy, and the former drug company executive told a Senate panel that pharmacy benefits managers negotiate drug prices for Medicare Part D, which he said is "the kind of thing where we could save money and improve things for patients" in connection with Part B prescription drugs.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription